

Peptide Array, SARS-Related Coronavirus 2 Non-Structural Protein 12 (NSP12)

Catalog No. NR-58700

This reagent is the property of the U.S. Government.

Product Description:

The 185-peptide array spans the non-structural protein 12 (NSP12) of the WIV04 strain of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2; GenPept: [QHR63259](#)). Peptides are 12- to 16-mers, with 9 to 11 amino acid overlaps. **Note:** The label for box three says it contains peptides 160 to 185. Box three contains peptides 161 to 185.

Lot: 2221898

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

The following information applies to all peptides:

- Appearance Off-white lyophilized powder
- Mass spectral analysis Correct MW by MALDI or Electrospray
- Counter Ion Trifluoroacetate

Peptide-specific information is shown in the tables and figures below.

Table 1: Peptide Analysis

Peptide	Date of Manufacturing	Length	Sequence	Molecular Weight (amu)	Purity by HPLC ¹	Peptide Content ²
1 of 185	1/6/2023	15	1-SADAQSFLNRVCGVS-15	1552.70	94.07%	50.8%
2 of 185	1/6/2023	15	6-SFLNRVCGVSAARLT-20	1592.86	94.13%	74.3%
3 of 185	1/13/2023	15	11-VCGVSAARLTPCGTG-25	1390.62	97.29%	60.3%
4 of 185	1/6/2023	15	16-AARLTPCGTGTSTDV-30	1448.59	82.07%	90.7%
5 of 185	1/6/2023	15	21-PCGTGTSTDVVYRAF-35	1572.74	81.11%	69.6%
6 of 185	12/13/2022	15	26-TSTDVVYRAFDIYND-40	1777.89	94.15%	70.6%
7 of 185	12/8/2022	15	31-VYRAFDIYNDKVAGF-45	1776.99	83.06%	70.5%
8 of 185	12/8/2022	15	36-DIYNDKVAGFAKFLK-50	1728.00	94.48%	64.0%
9 of 185	12/13/2022	15	41-KVAGFAKFLKTNCCR-55	1685.06	96.30%	93.0%
10 of 185	12/8/2022	15	46-AKFLKTNCCRFQEKD-60	1830.13	81.29%	88.9%
11 of 185	12/12/2022	15	51-TNCCRFQEKDEDDNL-65	1828.93	99.67%	44.9%
12 of 185	12/8/2022	15	56-FQEKDEDDNLIDSYF-70	1876.93	84.28%	62.3%
13 of 185	1/6/2023	15	61-EDDNLIDSYFVVKRH-75	1849.01	96.74%	47.2%
14 of 185	12/8/2022	15	66-IDSYFVVKRHTFSNY-80	1875.10	82.90%	54.6%
15 of 185	12/8/2022	15	71-VVKRHTFSNYQHEET-85	1874.03	82.76%	78.2%
16 of 185	12/8/2022	15	76-TFSNYQHEETIYNLL-90	1871.02	91.08%	59.2%
17 of 185	12/8/2022	15	81-QHEETIYNLLKDCPA-95	1772.97	80.29%	70.3%
18 of 185	12/8/2022	15	86-IYNLLKDCPAVAKHD-100	1698.98	93.37%	79.8%
19 of 185	12/13/2022	15	91-KDCPAVAKHDFKFR-105	1808.11	95.24%	81.5%
20 of 185	12/8/2022	15	96-VAKHDFKFRIDGDM-110	1825.10	81.17%	54.1%
21 of 185	12/8/2022	15	101-FFKFRIDGDMVPHIS-115	1808.11	82.98%	95.9%
22 of 185	12/8/2022	15	106-IDGDMVPHISRQRLT-120	1736.99	89.63%	91.5%
23 of 185	12/8/2022	15	111-VPHISRQRLTKYTMA-125	1800.13	84.61%	99.0%

Table 1: Peptide Analysis (continued)

Peptide	Date of Manufacturing	Length	Sequence	Molecular Weight (amu)	Purity by HPLC ¹	Peptide Content ²
24 of 185	12/13/2022	15	116-RQRLTKYTMADLVYA-130	1828.14	93.48%	94.2%
25 of 185	12/8/2022	15	121-KYTMADLVYALRHF-135	1842.13	90.59%	66.7%
26 of 185	12/13/2022	15	126-DLVYALRHFDEGNCD-140	1765.90	92.06%	57.4%
27 of 185	12/8/2022	15	131-LRHFDEGNCDLKEI-145	1788.98	89.66%	72.0%
28 of 185	1/13/2023	15	136-EGNCDLKEILVTYN-150	1710.90	96.95%	54.9%
29 of 185	1/6/2023	15	141-TLKEILVTYNCCDDD-155	1743.94	87.49%	57.7%
30 of 185	1/6/2023	15	146-LVTYNCCDDDYFNKK-160	1840.03	94.05%	62.6%
31 of 185	12/8/2022	15	151-CCDDDYFNKKDWYDF-165	1976.10	88.44%	86.4%
32 of 185	12/8/2022	15	156-YFNKKDWYDFVENPD-170	1979.11	94.21%	62.7%
33 of 185	12/8/2022	15	161-DWYDFVENPDILRVY-175	1943.13	86.26%	60.5%
34 of 185	12/8/2022	15	166-VENPDILRVYANLGE-180	1700.89	99.20%	86.6%
35 of 185	12/8/2022	15	171-ILRVYANLGERVRQA-185	1757.05	94.40%	44.1%
36 of 185	1/6/2023	15	176-ANLGERVRQALLKTV-190	1666.97	94.14%	65.9%
37 of 185	1/6/2023	15	181-RVRQALLKTVQFCDA-195	1747.07	84.34%	64.2%
38 of 185	12/8/2022	15	186-LLKTVQFCDAMRNAG-200	1665.97	81.38%	86.0%
39 of 185	12/28/2022	14	192-FCDAMRNAGIVGVL-205	1464.74	80.24%	66.2%
40 of 185	12/13/2022	15	196-MRNAGIVGVLTLDNQ-210	1599.85	97.00%	68.7%
41 of 185	12/13/2022	15	201-IVGVLTLDNQDLNGN-215	1583.74	86.21%	42.2%
42 of 185	12/21/2022	15	206-TLDNQLNGNWDYDFG-220	1770.81	98.14%	87.7%
43 of 185	1/5/2023	15	211-DLNGNWDYDFGDFIQT-225	1803.88	85.24%	43.9%
44 of 185	12/8/2022	15	216-WYDFGDFIQTTPGSG-230	1689.78	91.75%	84.9%
45 of 185	12/8/2022	15	221-DFIQTTPGSGVPVVD-235	1530.68	80.18%	81.1%
46 of 185	12/8/2022	15	226-TPGSGVPVVDSSYSL-240	1539.68	84.47%	71.9%
47 of 185	12/13/2022	15	231-VPVVDSSYSLMPIL-245	1708.07	93.88%	55.3%
48 of 185	12/8/2022	15	236-SYSLMPILTLTRA-250	1741.10	84.11%	81.9%
49 of 185	12/15/2022	15	241-LMPILTLTRALTAES-255	1628.97	98.65%	50.7%
50 of 185	12/8/2022	15	246-TLTRALTAESHVDTD-260	1628.74	85.10%	63.2%
51 of 185	12/8/2022	15	251-LTAESHVDTDLTKPY-265	1688.83	86.61%	68.4%
52 of 185	12/8/2022	15	256-HVDTLTKPYIKWDL-270	1843.09	88.27%	89.7%
53 of 185	12/8/2022	15	261-LTKPYIKWDLKYDF-275	1942.31	82.49%	63.8%
54 of 185	12/8/2022	15	266-IKWDLKYDFTEERL-280	1968.26	83.40%	49.7%
55 of 185	12/8/2022	15	271-LKYDFTEERLKLFD-285	1972.25	91.30%	69.9%
56 of 185	12/8/2022	15	276-TEERLKLFDYFKYW-290	2093.40	86.86%	65.5%
57 of 185	12/8/2022	15	281-KLFDYFKYWDQTYH-295	2109.35	80.71%	62.2%
58 of 185	12/8/2022	15	286-YFKYWDQTYHPNCVN-300	1977.16	94.18%	76.4%
59 of 185	12/8/2022	15	291-DQTYHPNCVNCLDDR-305	1791.91	86.02%	59.6%
60 of 185	1/5/2023	15	296-PNCVNCLDDRCILHC-310	1717.01	80.89%	52.1%
61 of 185	1/5/2023	15	301-CLDDRCILHCANFNV-315	1735.01	86.21%	83.2%
62 of 185	1/5/2023	15	306-CILHCANFNVLFSTV-320	1679.99	91.51%	42.3%
63 of 185	1/6/2023	15	311-ANFNVLFSTVFPPTS-325	1639.85	Crude ³	54.9%
64 of 185	12/15/2022	15	316-LFSTVFPPTSFGPLV-330	1607.89	94.02%	74.6%
65 of 185	12/15/2022	15	321-FPPTSFGPLVRKIFV-335	1704.07	81.34%	80.1%

Table 1: Peptide Analysis (continued)

Peptide	Date of Manufacturing	Length	Sequence	Molecular Weight (amu)	Purity by HPLC ¹	Peptide Content ²
66 of 185	12/15/2022	15	326-FGPLVRKIFVDGVPF-340	1690.04	98.46%	88.6%
67 of 185	12/15/2022	15	331-RKIFVDGVFVSTG-345	1619.91	98.23%	69.6%
68 of 185	12/15/2022	15	336-DGVFVSTGYHFRE-350	1708.87	89.28%	76.1%
69 of 185	12/15/2022	15	341-VVSTGYHFRELGVVH-355	1698.92	90.72%	66.4%
70 of 185	12/15/2022	15	346-YHFRELGVVHNQDVN-360	1825.98	91.03%	88.8%
71 of 185	12/15/2022	15	351-LGVVHNQDVNLHSSR-365	1673.83	81.72%	90.0%
72 of 185	12/15/2022	15	356-NQDVNLHSSRSLFKE-370	1772.92	96.88%	73.8%
73 of 185	12/15/2022	15	361-LHSSRSLFKELLVYA-375	1762.06	97.54%	75.8%
74 of 185	12/15/2022	15	366-LSFKELLVYAADPAM-380	1666.98	91.45%	77.2%
75 of 185	12/15/2022	15	371-LLVYAADPAMHAASG-385	1485.70	91.16%	89.1%
76 of 185	12/15/2022	15	376-ADPAMHAASGNLLLD-390	1494.66	92.46%	80.6%
77 of 185	12/15/2022	15	381-HAASGNLLLDKRTTC-395	1598.82	86.29%	63.3%
78 of 185	1/6/2023	15	386-NLLLDKRTTCFSVAA-400	1650.94	95.39%	83.8%
79 of 185	12/13/2022	15	391-KRTTCFSVAALTNNV-405	1623.87	80.88%	89.3%
80 of 185	12/13/2022	15	396-FSVAALTNNVAFQTV-410	1580.78	82.91%	93.5%
81 of 185	12/13/2022	15	401-LTNNVAFQTVKPGNF-415	1648.86	81.09%	85.5%
82 of 185	12/13/2022	15	406-AFQTVKPGNFNKDFY-420	1774.98	83.70%	51.9%
83 of 185	12/13/2022	15	411-KPGNFNKDFYDFAVS-425	1747.91	93.61%	84.0%
84 of 185	12/13/2022	15	416-NKDFYDFAVSKGFFK-430	1812.04	96.58%	74.6%
85 of 185	12/13/2022	15	421-DFAVSKGFFKEGSSV-435	1603.77	86.32%	43.0%
86 of 185	12/13/2022	15	426-KGFFKEGSSVELKHF-440	1738.99	95.52%	86.7%
87 of 185	12/13/2022	15	431-EGSSVELKHFFFAQD-445	1739.88	98.83%	48.1%
88 of 185	12/15/2022	15	436-ELKHFFFAQDGNAAI-450	1706.90	98.87%	58.1%
89 of 185	12/15/2022	15	441-FFAQDGNAAISDYDY-455	1695.74	84.21%	82.5%
90 of 185	12/15/2022	15	446-GNAAISDYDYRYNL-460	1796.89	86.07%	73.8%
91 of 185	12/20/2022	15	451-SDYDYRYNLPTMCD-465	1918.06	98.40%	71.2%
92 of 185	12/15/2022	15	456-YRYNLPTMCDIRQLL-470	1898.25	96.58%	87.4%
93 of 185	12/20/2022	15	461-PTMCDIRQLLFVVEV-475	1762.14	Crude ³	64.1%
94 of 185	12/15/2022	15	466-IRQLLFVVEVVDKYF-480	1867.24	97.84%	45.8%
95 of 185	12/19/2022	15	471-FVVEVVDKYFDCYDG-485	1796.99	86.40%	52.8%
96 of 185	12/13/2022	15	476-VDKYFDCYDGGCINA-490	1681.83	80.08%	64.5%
97 of 185	1/5/2023	15	481-DCYDGGCINANQVIV-495	1582.75	Crude ³	60.2%
98 of 185	1/13/2023	15	486-GCINANQVIVNLDK-500	1613.83	93.41%	54.4%
99 of 185	1/5/2023	15	491-NQVIVNLDKSAGFP-505	1614.80	93.68%	95.1%
100 of 185	12/19/2022	15	496-NNLDKSAGFPFNKVG-510	1693.86	95.27%	54.0%
101 of 185	12/12/2022	15	501-SAGFPFNKVGKARLY-515	1741.01	96.66%	54.7%
102 of 185	12/12/2022	15	506-FNKVGKARLYDSMS-520	1865.12	95.37%	52.7%
103 of 185	12/12/2022	15	511-KARLYDSMSYEDQD-525	1883.00	85.44%	62.2%
104 of 185	12/21/2022	15	516-YDSMSYEDQDALFAY-530	1816.89	89.01%	97.5%
105 of 185	1/6/2023	15	521-YEDQDALFAYTKRNV-535	1831.98	93.92%	63.6%
106 of 185	12/19/2022	15	526-ALFAYTKRNVITIT-540	1707.03	84.19%	63.8%
107 of 185	1/5/2023	15	531-TKRNVITITQMNLK-545	1756.12	94.43%	58.8%

Table 1: Peptide Analysis (continued)

Peptide	Date of Manufacturing	Length	Sequence	Molecular Weight (amu)	Purity by HPLC ¹	Peptide Content ²
108 of 185	1/5/2023	15	536-IPTITQMNLKYAISA-550	1662.99	88.65%	53.2%
109 of 185	1/5/2023	14	542-MNLKYAISAKNRAR-555	1634.94	94.86%	48.4%
110 of 185	1/5/2023	15	546-YAISAKNRARTVAGV-560	1575.81	97.71%	63.1%
111 of 185	1/13/2023	15	551-KNRARTVAGVSICST-565	1561.80	87.00%	84.1%
112 of 185	12/13/2022	15	556-TVAGVSICSTMTNRQ-570	1566.79	95.19%	84.2%
113 of 185	12/13/2022	15	561-SICSTMTNRQFHQKL-575	1793.07	97.12%	85.5%
114 of 185	1/13/2023	15	566-MTNRQFHQKLLKSIA-580	1814.16	92.14%	72.5%
115 of 185	12/13/2022	15	571-FHQKLLKSIAATRGA-585	1639.94	95.32%	65.9%
116 of 185	1/13/2023	15	576-LKSIAATRATVIGV-590	1455.74	85.81%	60.7%
117 of 185	1/9/2023	15	581-ATRATVIGTSKIFY-595	1569.80	97.57%	69.5%
118 of 185	1/5/2023	15	586-TVIGTSKIFYGGWHN-600	1664.86	94.69%	47.8%
119 of 185	1/5/2023	15	591-TSKIFYGGWHNMLKTV-605	1768.05	91.02%	57.7%
120 of 185	1/5/2023	15	596-GGWHNMLKTVYSDVE-610	1734.93	82.39%	74.0%
121 of 185	1/5/2023	15	601-MLKTVYSDVENPHLM-615	1776.08	91.46%	62.9%
122 of 185	1/5/2023	15	606-YSDVENPHLMGWDYP-620	1821.96	97.38%	61.2%
123 of 185	1/5/2023	15	611-NPHLMGWDYPKCDRA-625	1802.04	97.93%	91.4%
124 of 185	1/5/2023	15	616-GWDYPKCDRAMPNML-630	1796.09	95.81%	58.7%
125 of 185	12/19/2022	15	621-KCDRAMPNMLRIMAS-635	1736.14	92.88%	62.3%
126 of 185	1/5/2023	15	626-MPNMLRIMASLVLAR-640	1715.19	80.24%	48.2%
127 of 185	12/19/2022	15	631-RIMASLVLARKHTTC-645	1699.09	81.12%	62.6%
128 of 185	12/15/2022	15	636-LVLARKHTTCCSLSH-650	1667.99	98.68%	61.0%
129 of 185	12/13/2022	15	641-KHTTCCSLSHRFYRL-655	1851.16	97.41%	58.8%
130 of 185	12/15/2022	15	646-CSLSHRFYRLANECA-660	1769.01	93.35%	61.2%
131 of 185	1/6/2023	15	651-RFYRLANECAQVLSE-665	1798.03	80.90%	65.1%
132 of 185	1/6/2023	15	656-ANECAQVLSEVMCG-670	1583.85	85.74%	96.2%
133 of 185	1/6/2023	14	662-VLSEVMCGSLYV-675	1486.80	Crude ³	54.9%
134 of 185	1/5/2023	15	666-MVMCGSLYVKPGGT-680	1498.82	80.36%	71.8%
135 of 185	1/5/2023	15	671-GSLYVKPGGTSSGDA-685	1394.48	97.02%	82.8%
136 of 185	1/5/2023	15	676-KPGGTSSGDATTAYA-690	1382.43	99.96%	79.7%
137 of 185	12/13/2022	15	681-SSGDATTAYANSVFN-695	1503.52	91.27%	50.8%
138 of 185	12/12/2022	15	686-TTAYANSVFNICQAV-700	1600.79	Crude ³	85.9%
139 of 185	12/12/2022	15	691-NSVFNICQAVTANVN-705	1592.77	Crude ³	51.4%
140 of 185	1/6/2023	15	696-ICQAVTANVNALLST-710	1516.76	Crude ³	64.2%
141 of 185	1/5/2023	15	701-TANVNALLSTDGNGKI-715	1529.69	80.48%	94.3%
142 of 185	1/5/2023	15	706-ALLSTDGNGKIADKYV-720	1606.82	93.36%	62.7%
143 of 185	1/5/2023	15	711-DGNGKIADKYVRNLQH-725	1769.96	93.78%	91.0%
144 of 185	1/5/2023	15	716-ADKYVRNLQHRLYEC-730	1907.16	88.00%	71.7%
145 of 185	12/19/2022	15	721-RNLQHRLYECLYRNR-735	2033.32	89.47%	56.4%
146 of 185	1/5/2023	15	726-RLYECLYRNRDVTDT-740	1930.10	98.19%	72.9%
147 of 185	1/5/2023	15	731-LYRNRDVTDFVNEF-745	1902.03	93.84%	97.1%
148 of 185	12/19/2022	15	736-DVDTDFVNEFYAYLR-750	1866.00	87.52%	94.9%
149 of 185	1/5/2023	15	741-FVNEFYAYLRKHFSM-755	1951.26	90.72%	75.2%

Table 1: Peptide Analysis (continued)

Peptide	Date of Manufacturing	Length	Sequence	Molecular Weight (amu)	Purity by HPLC ¹	Peptide Content ²
150 of 185	1/13/2023	15	746-YAYLRKHFSSMILSD-760	1874.23	Crude ³	58.7%
151 of 185	12/19/2022	15	751-KHFSMILSDDAVVC-765	1695.02	88.11%	63.0%
152 of 185	1/13/2023	15	756-MILSDDAVVCFNSTY-770	1676.90	Crude ³	97.0%
153 of 185	12/19/2022	15	761-DAVVCFNSTYASQGL-775	1573.72	Crude ³	81.5%
154 of 185	12/19/2022	15	766-FNSTYASQGLVASIK-780	1584.77	95.54%	96.5%
155 of 185	12/19/2022	15	771-ASQGLVASIKNFKSV-785	1547.80	92.16%	69.1%
156 of 185	1/5/2023	15	776-VASIKNFKSVLYYQN-790	1773.04	80.14%	72.0%
157 of 185	12/19/2022	15	781-NFKSVLYYQNNVFMMS-795	1853.10	94.39%	37.8%
158 of 185	1/6/2023	15	786-LYYQNNVFMSEAKCW-800	1895.16	90.91%	77.7%
159 of 185	12/19/2022	15	791-NVFMSEAKCWETETDL-805	1772.99	93.71%	55.2%
160 of 185	1/6/2023	15	796-EAKCWETETDLTKGPH-810	1714.89	81.22%	63.8%
161 of 185	12/15/2022	15	801-TETDLTKGPHEFCSQ-815	1691.81	97.11%	55.7%
162 of 185	12/15/2022	15	806-TKGPHEFCSQHTMLV-820	1713.97	97.29%	55.8%
163 of 185	1/10/2023	15	811-EFCSQHTMLVKQGDD-825	1736.91	91.54%	55.1%
164 of 185	12/15/2022	15	816-HTMLVKQGDDYVYLP-830	1778.04	95.68%	80.8%
165 of 185	12/15/2022	15	821-KQGDDYVYLPYDPS-835	1755.88	85.81%	87.2%
166 of 185	12/15/2022	15	826-YVYLPYDPSRILGA-840	1722.98	98.59%	80.5%
167 of 185	12/15/2022	15	831-YDPSRILGAGCFVD-845	1608.81	98.89%	58.8%
168 of 185	12/15/2022	15	836-RILGAGCFVDDIVKT-850	1605.90	97.06%	49.4%
169 of 185	12/15/2022	15	841-GCFVDDIVKTGTLM-855	1612.86	96.43%	60.7%
170 of 185	12/15/2022	15	846-DIVKTGTLMIERFV-860	1736.04	95.51%	67.4%
171 of 185	1/6/2023	15	851-DGTLMIERFVSLAID-865	1678.94	96.90%	93.3%
172 of 185	12/20/2022	15	856-IERFVSLAIDAYPLT-870	1706.98	86.10%	44.6%
173 of 185	12/21/2022	15	861-SLAIDAYPLTKHPNQ-875	1666.88	97.45%	71.9%
174 of 185	12/21/2022	15	866-AYPLTKHPNQEYADV-880	1744.90	97.00%	79.0%
175 of 185	12/21/2022	15	871-KHPNQEYADVFLYL-885	1873.08	97.80%	62.9%
176 of 185	12/20/2022	15	876-EYADVFLYLQYIRK-890	1957.24	95.93%	64.4%
177 of 185	12/21/2022	15	881-FHLYLQYIRKLHDEL-895	1987.31	97.89%	57.3%
178 of 185	1/10/2023	14	887-YIRKLHDELGHML-900	1725.02	94.20%	53.8%
179 of 185	12/21/2022	15	891-LHDELGHMLDMYSV-905	1759.99	97.96%	84.0%
180 of 185	12/21/2022	15	896-TGHMLDMYSVMLTND-910	1726.98	80.99%	59.2%
181 of 185	12/21/2022	15	901-DMYSVMLTNDNTSRY-915	1808.98	94.49%	61.5%
182 of 185	12/21/2022	15	906-MLTNDNTSRYWEPEF-920	1902.05	96.25%	74.7%
183 of 185	12/20/2022	15	911-NTSRYWEPEFYEAMY-925	1985.14	83.86%	73.8%
184 of 185	12/21/2022	15	916-WEPEFYEAMYPHTV-930	1899.09	93.17%	61.0%
185 of 185	12/21/2022	12	921-YEAMYPHTVLQ-932	1452.64	94.94%	67.3%

¹Percent full length

²Remainder is salt and water

³Due to the hydrophobic nature of these peptides, purity could not be performed by HPLC. Purity was tested by mass spectrometry.

Figure 1: Amino Acid Analysis⁴

Peptide		Ala (A)	Arg (R)	Asx (N,D)	Cys (C)	Glx (Q,E)	Gly (G)	His (H)	Ile (I)	Leu (L)	Lys (K)	Met (M)	Phe (F)	Pro (P)	Ser (S)	Thr (T)	Trp (W)	Tyr (Y)	Val (V)
1 of 185	Expected	2	1	2	1	1	1			1			1		3				2
	Actual	2.0	1.1	1.8	0.8	1.2	1.0			1.1			1.0		3.0				2.0
2 of 185	Expected	2	2	1	1	0	1			2			1		2	1			2
	Actual	2.0	2.1	0.8	0.7		1.0			2.2			1.0		1.9	1.0			2.0
3 of 185	Expected	2	1		2		3			1				1	1	2			2
	Actual	1.8	1.0		1.8		3.0			1.2				0.8	0.9	2.3			1.9
4 of 185	Expected	2	1	1	1		2			1				1	1	4			1
	Actual	1.9	1.0	0.8	0.6		2.1			1.1				0.9	1.0	4.0			1.2
5 of 185	Expected	1	1	1	1		2						1	1	1	3		1	2
	Actual	1.2	1.2	1.1	0.9		2.0						1.1	1.1	1.0	2.8		1.0	1.8
6 of 185	Expected	1	1	4					1				1		1	2		2	2
	Actual	0.8	0.9	3.8					1.2				1.1		1.1	2.0		1.9	2.0
7 of 185	Expected	2	1	3			1		1		1		2					2	2
	Actual	2.0	1.0	3.0			1.2		1.2		1.0		2.2					2.0	1.8
8 of 185	Expected	2	0	3			1		1	1	3		2					1	1
	Actual	2.0	0.0	2.7			1.2		1.0	1.1	3.2		2.0					1.0	1.2
9 of 185	Expected	2	1	1	2		1			1	3		2			1			1
	Actual	2.0	1.1	0.8	1.8		1.0			1.0	3.0		2.0			0.8			1.0
10 of 185	Expected	1	1	2	2	2				1	3		2			1			
	Actual	1.1	0.9	1.9	1.6	2.0				1.0	3.0		2.0			0.9			
11 of 185	Expected		1	5	2	3				1	1		1			1			
	Actual		0.9	5.3	1.6	3.1				1.0	1.1		1.1			1.1			
12 of 185	Expected			5		3			1	1	1		2		1			1	
	Actual			5.4		3.0			1.1	1.0	0.9		2.0		0.9			1.0	
13 of 185	Expected		1	4		1		1	1	1	1		1		1			1	2
	Actual		1.0	3.8		1.0		0.9	1.0	1.0	1.0		0.8		1.0			0.9	2.0
14 of 185	Expected		1	2				1	1		1		2		2	1		2	2
	Actual		1.0	2.0				1.2	1.2		1.0		2.0		2.0	1.3		2.0	1.7
15 of 185	Expected		1	1		3		2			1		1		1	2		1	2
	Actual		1.1	1.0		3.0		2.1			1.0		1.1		1.0	2.1		0.9	2.0
16 of 185	Expected			2		3		1	1	2			1		1	2		2	
	Actual			2.1		2.8		1.2	1.1	2.0			1.0		1.0	2.0		1.8	
17 of 185	Expected	1		2	1	3		1	1	2	1			1		1		2	
	Actual	1.0		2.2	0.8	3.1		0.8	0.9	1.8	1.1			1.0		1.0		1.8	
18 of 185	Expected	2		3	1			1	1	2	2			1				1	1
	Actual	2.0		3.1	0.8			0.8	1.0	2.0	2.0			1.0				0.8	1.1
19 of 185	Expected	2	1	2	1			1			3		3	1					1
	Actual	2.0	1.0	1.8	0.8			0.9			3.0		3.0	1.0					0.9
20 of 185	Expected	1	1	3			1	1	1		2	1	3						1
	Actual	1.0	1.0	3.1			1.0	1.0	1.0		2.0	0.8	3.0						1.0
21 of 185	Expected		1	2			1	1	2		1	1	3	1	1				1
	Actual		0.9	1.9			1.0	1.0	1.8		1.0	0.8	3.0	1.1	1.0				1.0
22 of 185	Expected		2	2		1	1	1	2	1		1		1	1	1			1
	Actual		2.1	2.0		1.0	1.0	1.0	1.9	1.0		0.9		1.0	1.0	1.1			1.0
23 of 185	Expected	1	2	0		1		1	1	1	1	1		1	1	2		1	1
	Actual	1.1	2.0	0.0		0.9		1.0	0.8	1.1	0.8	0.8		1.0	0.8	2.0		0.7	0.9
24 of 185	Expected	2	2	1		1				2	1	1				2		2	1
	Actual	2.0	2.1	0.9		0.9				2.0	0.8	0.9				1.8		1.7	0.8

Figure 1: Amino Acid Analysis (continued)⁴

Peptide		Ala (A)	Arg (R)	Asx (N,D)	Cys (C)	Glx (Q,E)	Gly (G)	His (H)	Ile (I)	Leu (L)	Lys (K)	Met (M)	Phe (F)	Pro (P)	Ser (S)	Thr (T)	Trp (W)	Tyr (Y)	Val (V)
25 of 185	Expected	2	1	2				1		2	1	1	1					2	1
	Actual	2.0	1.0	2.0				1.2		2.0	1.2	0.8	1.0					2.0	1.0
26 of 185	Expected	1	1	4	1	1	1	1		2			1					1	1
	Actual	1.0	1.0	3.9	0.7	1.1	0.0	0.9		1.9			1.0					0.7	0.9
27 of 185	Expected		1	3	1	2	1	1	1	2	1		1			1			
	Actual		0.9	3.1	0.8	2.2	1.0	1.0	1.0	2.0	0.9		1.0			1.0			
28 of 185	Expected			3	1	2	1		1	2	1					2		1	1
	Actual			3.0	0.7	1.7	1.0		1.1	1.7	1.1					2.0		0.9	1.0
29 of 185	Expected			4	2	1			1	2	1					2		1	1
	Actual			3.8	1.7	1.0			1.1	2.1	0.9					2.0		0.7	1.2
30 of 185	Expected	1.0	1	3	0	1	2		1	2		1				1			2
	Actual	1.1	1.1	3.1	0.0	1.1	2.0		0.9	2.3		1.0				1.0			1.9
31 of 185	Expected			6	2						2		2				1	2	
	Actual			6.3	1.8						2.0		1.7				b	1.7	
32 of 185	Expected			5		1					2		2	1			1	2	1
	Actual			4.8		1.1					2.0		2.0	1.1			b	1.6	1.1
33 of 185	Expected		1	4		1			1	1			1	1			1	2	2
	Actual		1.1	4.7		1.0			1.0	1.2			1.0	1.3			b	1.7	2.0
34 of 185	Expected	1	1	3		2	1		1	2				1				1	2
	Actual	1.1	0.8	3.0		2.0	1.0		1.0	2.1				1.0				0.8	1.8
35 of 185	Expected	2	3	1		2	1		1	2								1	2
	Actual	2.0	3.2	1.2		2.0	1.0		1.1	2.0								0.8	2.0
36 of 185	Expected	2	2	1		2	1			3	1					1			2
	Actual	2.0	2.1	1.1		2.2	0.0			3.0	1.1					1.0			2.0
37 of 185	Expected	2	2	1	1	2	0			2	1		1			1			2
	Actual	2.1	1.8	1.1	0.9	2.2	0.0			2.1	1.1		0.9			1.0			1.8
38 of 185	Expected	2	1	2	1	1	1			2	1	1	1			1			1
	Actual	1.9	0.8	1.8	0.8	0.9	0.8			2.0	1.1	1.0	1.0			1.0			1.0
39 of 185	Expected	2	1	2	1		2		1	1		1	1						2
	Actual	2.2	1.0	1.9	0.8		2.0		1.0	0.7		0.9	1.0						2.0
40 of 185	Expected	1	1	3		1	2		1	2		1				1			2
	Actual	1.0	1.0	3.0		1.1	2.0		0.9	2.0		1.0				1.0			1.9
41 of 185	Expected			5		1	2		1	3						1			2
	Actual			5.0		1.0	2.0		1.0	3.0						1.2			1.8
42 of 185	Expected			6		1	2			2			1			1	1	1	
	Actual			6.2		1.1	2.0			2.3			1.1			1.0	b	0.8	
43 of 185	Expected			5		1	2		1	1			2			1	1	1	
	Actual			5.0		1.1	2.0		1.0	1.0			2.0			1.0	b	0.7	
44 of 185	Expected			2		1	3		1				2	1	1	2	1	1	
	Actual			2.1		1.0	4.0		0.8				2.0	0.9	1.2	2.0	b	0.7	
45 of 185	Expected			2		1	2		1				1	2	1	2			3
	Actual			1.8		0.8	2.0		1.0				1.0	2.0	1.1	2.0			2.9
46 of 185	Expected			1			2			1				2	3	1		2	3
	Actual			1.0			2.0			1.0				2.0	3.0	1.2		2.0	3.2
47 of 185	Expected			1					1	3		1		2	2			2	3
	Actual			0.8					1.0	3.0		1.0		2.2	2.3			1.8	2.8
48 of 185	Expected	1	1						1	4		1		1	2	2		2	
	Actual	1.1	0.7						1.0	4.0		1.0		0.9	1.8	1.8		1.7	

Figure 1: Amino Acid Analysis (continued)⁴

Peptide		Ala (A)	Arg (R)	Asx (N,D)	Cys (C)	Glx (Q,E)	Gly (G)	His (H)	Ile (I)	Leu (L)	Lys (K)	Met (M)	Phe (F)	Pro (P)	Ser (S)	Thr (T)	Trp (W)	Tyr (Y)	Val (V)
49 of 185	Expected	2	1			1			1	4		1		1	1	3			
	Actual	2.0	1.1			1.0			1.1	4.0		1.0		1.0	1.7	3.1			
50 of 185	Expected	2	1	2		1		1		2					1	4			1
	Actual	2.1	1.2	2.0		1.2		0.8		1.9					1.2	3.8			1.0
51 of 185	Expected	1		2		1		1		2	1			1	1	3		1	1
	Actual	1.1		2.0		1.1		1.0		2.1	1.0			1.1	1.1	3.0		0.8	0.9
52 of 185	Expected			3				1	1	2	2			1		2	1	1	1
	Actual			3.0				1.0	1.2	2.0	1.9			1.2		2.0	b	0.7	0.9
53 of 185	Expected			2					1	3	3		1	1		1	1	2	
	Actual			2.0				0.9	3.0	3.0			0.9	1.1		1.3	b	1.8	
54 of 185	Expected		1	2		2			1	3	2		1			1	1	1	
	Actual		0.9	2.1		2.0			0.8	3.0	2.0		1.0			1.0	b	0.8	
55 of 185	Expected		2	2		2				3	2		2			1		1	
	Actual		1.8	2.0		1.8				3.0	2.0		2.0			1.0		1.7	
56 of 185	Expected		2	1		2				2	2		2			1	1	2	
	Actual		1.9	1.0		2.1				1.8	1.8		1.9			1.2	b	1.8	
57 of 185	Expected		1	2		1		1		1	2		2			1	1	3	
	Actual		0.9	2.1		1.0		1.0		1.2	2.1		1.9			1.0	b	2.8	
58 of 185	Expected		0	3	1	1		1			1		1	1		1	1	3	1
	Actual		0.0	3.2	0.8	1.0		1.0			0.7		1.0	1.2		1.0	b	2.7	1.3
59 of 185	Expected		1	5	2	1		1		1				1		1		1	1
	Actual		0.9	5.1	1.8	1.0		1.0		1.0				1.1		1.0		0.7	1.0
60 of 185	Expected		1	4	4			1	1	2				1					1
	Actual		0.7	4.1	3.5			1.2	1.1	2.0				1.0					1.1
61 of 185	Expected	1	1	4	3			1	1	2			1						1
	Actual	1.1	1.1	3.9	2.8			0.9	0.9	1.7			1.1						1.2
62 of 185	Expected	1		2	2			1	1	2			2		1	1			2
	Actual	1.1		1.8	1.9			0.8	1.0	2.0			1.8		1.0	1.2			2.1
63 of 185	Expected	1		2						1			3	2	2	2			2
	Actual	0.9		1.9						0.9			3.1	2.0	1.0	1.8			2.0
64 of 185	Expected						1			2			3	3	2	2			2
	Actual						1.0			1.9			2.8	3.0	1.9	1.9			2.2
65 of 185	Expected		1				1		1	1	1		3	3	1	1			2
	Actual		1.0				1.0		0.8	0.9	0.8		3.0	3.0	1.0	0.8			1.9
66 of 185	Expected		1	1			2		1	1	1		3	2					3
	Actual		1.1	1.1			2.1		1.0	1.0	1.0		3.0	2.1					3.0
67 of 185	Expected		1	1			2		1		1		2	1	1	1			4
	Actual		0.7	1.2			2.0		1.2		1.0		2.2	1.0	1.2	1.0			3.9
68 of 185	Expected		1	1		1	2	1					2	1	1	1		1	3
	Actual		1.0	1.1		1.1	2.2	1.2					2.2	1.0	1.1	1.0		0.7	2.6
69 of 185	Expected		1			1	2	2		1			1		1	1		1	4
	Actual		0.9			1.0	2.0	2.0		1.2			1.2		0.7	1.2		0.7	4.0
70 of 185	Expected		1	3		2	1	2		1			1					1	3
	Actual		1.0	3.1		2.1	1.0	2.0		1.1			0.8					0.9	3.0
71 of 185	Expected		1	3		1	1	2		2					2				3
	Actual		1.2	3.0		1.0	1.0	1.7		1.9					2.0				3.0
72 of 185	Expected		1	3		2		1		2	1		1		3				1
	Actual		1.2	2.8		1.9		1.2		2.0	1.0		1.0		3.0				1.0

Figure 1: Amino Acid Analysis (continued)⁴

Peptide		Ala (A)	Arg (R)	Asx (N,D)	Cys (C)	Glx (Q,E)	Gly (G)	His (H)	Ile (I)	Leu (L)	Lys (K)	Met (M)	Phe (F)	Pro (P)	Ser (S)	Thr (T)	Trp (W)	Tyr (Y)	Val (V)
73 of 185	Expected	1	1			1		1		4	1		1		3			1	1
	Actual	1.2	0.8			1.0		0.7		3.8	1.0		1.2		3.2			1.1	1.0
74 of 185	Expected	3		1		1				3	1	1	1	1	1			1	1
	Actual	3.0		1.0		1.3				3.4	1.1	1.0	1.0	1.0	1.0			0.9	0.8
75 of 185	Expected	5		1			1	1		2		1		1	1			1	1
	Actual	5.0		1.0			1.0	1.0		2.2		0.9		1.0	1.0			1.2	1.0
76 of 185	Expected	4		3			1	1		3		1		1	1				
	Actual	4.0		3.0			1.0	1.0		3.0		1.0		1.0	1.0				
77 of 185	Expected	2	1	2	1		1	1		3	1				1	2			
	Actual	2.0	0.8	2.0	1.0		1.0	1.0		3.0	0.9				1.0	2.0			
78 of 185	Expected	2	1	2	1					3	1		1		1	2			1
	Actual	2.1	0.8	1.8	0.9					3.0	0.8		1.2		1.1	2.0			1.2
79 of 185	Expected	2	1	2	1					1	1		1		1	3			2
	Actual	2.0	1.0	2.1	1.0					0.9	1.0		0.9		1.0	3.0			2.0
80 of 185	Expected	3		2		1				1			2		1	2			3
	Actual	3.0		1.9		1.1				0.9			1.7		1.0	2.1			2.7
81 of 185	Expected	1		3		1	1			1	1		2	1		2			2
	Actual	1.1		3.0		0.9	1.0			1.0	0.8		2.2	0.8		2.0			2.0
82 of 185	Expected	1		3		1	1				2		3	1		1		1	1
	Actual	1.0		3.1		0.9	1.0				2.0		3.0	1.1		0.7		0.8	1.0
83 of 185	Expected	1		4			1				2		3	1	1			1	1
	Actual	1.1		4.0			1.1				2.0		3.0	0.8	1.2			0.7	1.1
84 of 185	Expected	1		3			1				3		4		1			1	1
	Actual	1.1		3.1			1.2				3.0		4.0		1.2			0.8	1.1
85 of 185	Expected	1		1		1	2				2		3		3				2
	Actual	1.0		1.0		1.0	2.0				2.0		3.0		3.0				2.0
86 of 185	Expected					2	2	1		1	3		3		2				1
	Actual					2.0	2.1	1.0		1.1	2.8		2.7		1.8				0.8
87 of 185	Expected	1		1		3	1	1		1	1		3		2				1
	Actual	0.9		1.0		2.0	1.0	1.0		1.0	1.0		3.1		2.0				1.0
88 of 185	Expected	3		2		2	1	1	1	1	1		3						
	Actual	3.0		2.1		2.2	1.0	1.0	1.0	1.0	1.0		3.1						
89 of 185	Expected	3.0		4.0		1.0	1.0		1.0				2.0		1.0			2.0	
	Actual	3.0		4.1		1.2	1.0		1.0				2.2		1.0			1.7	
90 of 185	Expected	2	1	4			1		1	1					1			4	
	Actual	2.1	1.1	4.2			1.0		1.0	1.0					1.0			4.0	
91 of 185	Expected		1	4	1					1		1		1	1	1		4	
	Actual		1.2	3.7	0.8					1.1		1.0		1.0	1.2	1.0		3.5	
92 of 185	Expected		2	2	1	1			1	3		1		1		1		2	
	Actual		2.0	2.0	1.0	1.0			1.0	3.0		1.0		1.0		1.0		1.8	
93 of 185	Expected		1	1	1	2			1	2		1	1	1		1			3
	Actual		1.0	0.9	0.7	1.8			1.0	2.0		0.9	1.0	1.1		1.0			3.0
94 of 185	Expected		1	1		2			1	2	1		2					1	4
	Actual		1.0	1.0		2.1			1.2	2.3	1.0		2.0					1.2	3.8
95 of 185	Expected			3	1	1	1				1		2					2	4
	Actual			2.7	0.8	0.8	1.0				0.9		2.0					1.6	4.0
96 of 185	Expected	1		4	2		2		1		1		1					2	1
	Actual	1.1		4.1	2.0		2.0		1.1		1.1		1.2					2.0	0.8

Figure 1: Amino Acid Analysis (continued)⁴

Peptide		Ala (A)	Arg (R)	Asx (N,D)	Cys (C)	Glx (Q,E)	Gly (G)	His (H)	Ile (I)	Leu (L)	Lys (K)	Met (M)	Phe (F)	Pro (P)	Ser (S)	Thr (T)	Trp (W)	Tyr (Y)	Val (V)
97 of 185	Expected	1		4	2	1	2		2									1	2
	Actual	1.0		3.7	1.8	1.1	1.9		2.0									0.8	2.0
98 of 185	Expected	1		5	1	1	1		2	1	1								2
	Actual	0.8		5.0	0.9	0.8	1.0		2.0	1.0	1.0								2.0
99 of 185	Expected	1		4		1	1		1	1	1		1	1	1				2
	Actual	1.0		4.1		1.0	1.0		0.9	1.0	1.0		1.0	1.2	1.0				1.8
100 of 185	Expected	1		4			2			1	2		2	1	1			1	
	Actual	1.1		3.9			2.0			1.1	2.1		2.3	1.2	1.0			b	
101 of 185	Expected	2	1	1			2			1	2		2	1	1			1	1
	Actual	2.0	3.2	1.1			2.0			1.1	2.1		2.0	0.9	0.9			b	0.7
102 of 185	Expected	1	1	2			1			1	2	1	1		2			1	2
	Actual	1.0	2.5	2.1			1.0			1.0	2.2	0.8	1.2		1.8			b	2.0
103 of 185	Expected	1	1	3		2				1	1	1			2				3
	Actual	1.0	3.4	3.1		2.1				0.8	1.0	0.8			1.7				2.7
104 of 185	Expected	2		3		2				1		1	1		2				3
	Actual	1.8		3.0		2.1				1.0		0.9	0.9		2.0				2.6
105 of 185	Expected	2	1	3		2				1	1		1			1		2	1
	Actual	2.2	2.3	3.2		1.9				0.8	0.9		0.8			1.0		1.8	1.0
106 of 185	Expected	2	1	1					2	1	1		1	1		3		1	1
	Actual	2.2	1.1	1.0					1.9	1.0	1.2		1.0	1.0		2.8		0.8	0.8
107 of 185	Expected		1	2		1			2	1	2	1		1		3			1
	Actual		0.8	1.9		1.0			1.8	1.0	2.0	1.0		1.3		3.1			0.8
108 of 185	Expected	2	0	1		1			3	1	1	1		1	1	2		1	
	Actual	2.1	0.0	1.0		1.2			3.0	1.0	1.0	1.0		1.2	1.0	2.2		1.0	
109 of 185	Expected	3	2	2					1	1	2	1			1			1	
	Actual	3.1	2.2	1.7					1.2	1.0	2.0	1.1			1.0			1.0	
110 of 185	Expected	4	2	1			1		1		1				1	1		1	2
	Actual	4.1	1.8	1.0			1.0		1.1		1.0				0.9	1.3		0.8	2.0
111 of 185	Expected	2	2	1	1		1		1		1				2	2			2
	Actual	2.0	0.7	0.9	0.7		1.0		1.0		1.0				1.7	2.1			1.7
112 of 185	Expected	1	1	1	1	1	1		1			1			2	3			2
	Actual	1.0	0.6	0.9	0.7	1.0	1.0		1.0			1.0			2.0	3.0			2.0
113 of 185	Expected	0	1	1	1	2		1	1	1	1	1	1		2	2			
	Actual	0.0	0.1	1.1	0.7	1.9		1.0	1.0	1.0	1.0	0.9	1.0		2.0	2.0			
114 of 185	Expected	1	1	1		2		1	1	2	2	1	1		1	1			
	Actual	0.9	0.8	1.1		2.1		1.1	1.2	1.9	2.0	0.8	0.9		1.0	1.0			
115 of 185	Expected	3	1	0		1	1	1	1	2	2		1		1	1			
	Actual	2.9	0.9	0.0		1.1	1.1	1.1	1.0	1.7	1.8		0.8		1.0	1.0			
116 of 185	Expected	3	1				2		2	1	1				1	2			2
	Actual	2.8	1.5				2.0		2.2	0.9	0.9				1.0	2.0			1.7
117 of 185	Expected	2	1				2		1		1		1		1	3		1	2
	Actual	2.0	0.9				2.0		1.2		1.1		1.1		1.2	3.0		0.6	2.0
118 of 185	Expected			1			3	1	1		1		1		1	2	1	1	2
	Actual			1.2			3.0	1.0	1.1		1.2		1.2		1.0	2.0	b	0.9	2.0
119 of 185	Expected			1			2	1		1	2	1	1		1	2	1	1	1
	Actual			1.1			2.0	1.2		1.0	2.3	1.0	1.2		1.2	2.0	b	1.0	1.0
120 of 185	Expected			2		1	2	1		1	1	1			1	1	1	1	2
	Actual			2.2		1.0	2.0	1.0		1.0	1.1	0.8			1.0	1.0	b	1.0	2.0

Figure 1: Amino Acid Analysis (continued)⁴

Peptide		Ala (A)	Arg (R)	Asx (N,D)	Cys (C)	Glx (Q,E)	Gly (G)	His (H)	Ile (I)	Leu (L)	Lys (K)	Met (M)	Phe (F)	Pro (P)	Ser (S)	Thr (T)	Trp (W)	Tyr (Y)	Val (V)
121 of 185	Expected			2		1		1		2	1	2		1	1	1		1	2
	Actual			1.9		1.1		1.1		1.9	1.0	1.8		1.0	1.0	1.2		0.8	1.8
122 of 185	Expected			3		1	1	1		1		1		2	1		1	2	1
	Actual			3.8		1.0	1.0	1.0		1.0		1.0		2.0	1.0		b	1.7	1.0
123 of 185	Expected	1	1	3	1		1	1		1	1	1		2			1	1	
	Actual	1.1	0.9	3.1	0.8		1.0	0.8		1.0	0.8	1.0		2.0			b	0.8	
124 of 185	Expected	1	1	3	1		1			1		2		2			1	1	
	Actual	1.0	0.8	2.9	1.1		1.0			0.9		1.9		2.0			b	0.7	
125 of 185	Expected	2	2	2	1				1	1	1	3		1	1				
	Actual	2.0	2.1	2.1	0.7				0.9	0.7	1.0	2.9		1.0	0.8				
126 of 185	Expected	2	2	1	0				1	3		3		1	1				1
	Actual	2.1	2.0	0.9	0.0				1.1	2.7		3.0		1.0	1.1				
127 of 185	Expected	2	2		1			1	1	2	1	1			1	2			1
	Actual	2.1	2.1		0.7			1.0	1.0	2.0	0.9	1.0			1.0	1.9			
128 of 185	Expected	1	1		2			2		3	1				2	2			1
	Actual	0.9	0.9		1.8			1.9		3.0	0.7				2.0	2.0			
129 of 185	Expected	0	2		2			2		2	1		1		2	2			1
	Actual	0.0	2.6		1.7			2.0		2.3	1.2		1.2		1.9	1.7			1.1
130 of 185	Expected	2	2	1	2	1		1		2			1		2				1
	Actual	2.0	4.9	1.1	0.8	1.1		1.0		1.9			0.9		2.0				1.0
131 of 185	Expected	2	2	1	1	3				2			1		1				1
	Actual	2.1	6.5	0.9	0.9	2.9				2.0			1.0		0.8				0.7
132 of 185	Expected	2		1	2	3	1			1		2			1				2
	Actual	1.7		1.2	1.6	3.1	1.0			1.1		2.0			0.8				1.9
133 of 185	Expected				1	1	2			2		2			2				1
	Actual				1.7	1.0	1.7			1.8		1.7			1.8				0.8
134 of 185	Expected				1		4			1	1	2		1	1	1			1
	Actual				0.8		4.3			1.1	0.9	1.9		1.0	1.2	1.2			0.8
135 of 185	Expected	1		1			4			1	1			1	3	1			1
	Actual	1.0		0.9			4.1			1.0	1.0			1.0	3.0	1.0			0.8
136 of 185	Expected	3		1			3				1			1	2	3			1
	Actual	3.0		0.9			3.0				0.8			1.0	1.8	3.1			1.0
137 of 185	Expected	3		3			1						1		3	2			1
	Actual	3.1		2.9			1.0						1.0		3.0	1.7			0.7
138 of 185	Expected	3		2	1	1			1				1		1	2			1
	Actual	3.0		2.1	0.9	1.0			1.1				1.2		1.1	2.2			1.0
139 of 185	Expected	2		4	1	1			1				1		1	1			3
	Actual	2.0		4.1	0.7	1.0			1.0				1.0		1.1	1.7			3.0
140 of 185	Expected	3		2	1	1			1	2					1	2			2
	Actual	3.1		2.1	0.8	1.1			0.9	2.0					1.0	1.9			2.0
141 of 185	Expected	2		4			1		1	2	1				1	2			1
	Actual	2.1		4.0			1.0		1.2	2.0	1.1				1.0	2.0			1.0
142 of 185	Expected	2		3			1		1	2	2				1	1			1
	Actual	2.0		2.9			1.0		1.0	1.8	1.8				1.2	1.1			0.8
143 of 185	Expected	1	1	4		1	1	1	1	1	2								1
	Actual	0.9	0.8	3.9		1.0	1.0	0.9	0.9	1.1	1.9								0.8
144 of 185	Expected	1	2	2	1	2		1		2	1								2
	Actual	0.7	1.7	2.2	1.0	2.1		1.0		2.0	0.8								1.9

Figure 1: Amino Acid Analysis (continued)⁴

Peptide		Ala (A)	Arg (R)	Asx (N,D)	Cys (C)	Glx (Q,E)	Gly (G)	His (H)	Ile (I)	Leu (L)	Lys (K)	Met (M)	Phe (F)	Pro (P)	Ser (S)	Thr (T)	Trp (W)	Tyr (Y)	Val (V)
145 of 185	Expected		4	2	1	2		1		3								2	
	Actual		3.5	2.0	0.8	2.0		1.0		2.7								1.7	
146 of 185	Expected		3	4	1	1				2						1		2	1
	Actual		3.0	3.8	0.7	1.0				2.0						1.0		1.7	1.0
147 of 185	Expected		2	5		1				1			2			1		1	2
	Actual		1.7	4.8		1.1				0.9			1.9			1.0		0.8	1.8
148 of 185	Expected	1	1	4		1				1			2			1		2	2
	Actual	1.0	1.4	4.1		1.1				1.0			1.8			1.0		1.7	2.0
149 of 185	Expected	1	1	1		1		1		1	1	1	3		1			2	1
	Actual	1.1	0.9	1.1		1.0		1.0		1.0	0.9	0.7	3.0		1.2			1.8	1.0
150 of 185	Expected	1	1	1				1	1	2	1	2	1		2			2	
	Actual	1.0	0.8	1.0				0.9	1.2	1.9	0.9	1.9	1.0		2.0			1.7	
151 of 185	Expected	1		2	1			1	1	1	1	2	1		2				2
	Actual	0.7		2.0	0.8			1.0	1.0	1.0	0.7	1.8	1.0		1.8				2.0
152 of 185	Expected	1		3	1				1	1		1	1		2	1		1	2
	Actual	1.0		3.2	0.7				1.0	1.1		0.7	1.0		2.0	1.0		0.8	2.0
153 of 185	Expected	2		2	1	1	1			1			1		2	1		1	2
	Actual	2.0		2.0	1.0	1.2	1.0			1.0			0.9		2.0	1.0		0.8	2.0
154 of 185	Expected	2		1		1	1		1	1	1		1		3	1		1	1
	Actual	2.1		1.0		1.0	1.0		1.0	1.0	1.0		1.0		3.0	1.0		1.0	1.2
155 of 185	Expected	2		1		1	1		1	1	2		1		3				2
	Actual	2.1		1.2		1.1	1.1		1.1	0.8	2.0		1.0		3.0				2.0
156 of 185	Expected	1		2		1			1	1	2		1		2			2	2
	Actual	1.2		2.1		1.2			0.9	0.9	2.0		1.0		2.0			1.8	1.8
157 of 185	Expected			3		1				1	1	1	2		2			2	2
	Actual			3.1		1.0				1.0	1.0	1.0	1.9		2.0			1.8	2.0
158 of 185	Expected	1		2	1	2				1	1	1	1		1		1	2	1
	Actual	1.0		1.9	0.9	2.2				1.0	1.0	0.9	1.2		1.3		b	1.9	1.0
159 of 185	Expected	1		2	1	2				1	1	1	1		1	2	1		1
	Actual	1.1		1.8	0.7	2.0				1.0	1.0	0.9	0.8		0.9	2.2	b		1.0
160 of 185	Expected	1		1	1	2	1	1		1	2			1		3	1		
	Actual	1.0		1.1	1.0	1.9	1.0	1.0		1.1	2.0			1.0		3.0	b		
161 of 185	Expected			1	1	3	1	1		1	1		1	1	1	3			
	Actual			0.9	0.8	3.0	1.0	1.0		1.0	1.2		1.0	1.0	1.0	3.0			
162 of 185	Expected				1	2	1	2		1	1	1	1	1	1	2			1
	Actual				0.9	1.8	1.0	1.8		0.9	0.9	0.8	0.8	0.9	0.8	1.9			1.1
163 of 185	Expected			2	1	3	1	1		1	1	1	1		1	1			1
	Actual			1.8	1.0	2.2	0.9	1.1		1.2	1.0	0.9	0.7		0.8	1.2			1.0
164 of 185	Expected			2		1	1	1		2	1	1		1		1		2	2
	Actual			2.1		1.0	1.0	1.0		2.0	1.0	1.0		1.0		1.0		2.1	2.0
165 of 185	Expected			3		1	1			1	1			3	1			3	1
	Actual			3.0		1.0	1.0			1.0	1.0			3.0	1.0			2.7	1.0
166 of 185	Expected	1	1	1			1		1	2				3	1			3	1
	Actual	1.0	2.0	1.0			1.0		1.0	2.0				3.0	1.1			2.8	1.0
167 of 185	Expected	1	1	2	1		2		1	1			1	2	1			1	1
	Actual	1.1	1.4	2.1	1.0		2.0		1.1	1.1			1.0	2.0	0.7			0.8	1.0
168 of 185	Expected	1	1	2	1		2		2	1	1		1			1			2
	Actual	1.1	1.1	2.1	0.9		2.0		1.9	0.9	1.1		0.9			1.0			2.0

Figure 1: Amino Acid Analysis (continued)⁴

Peptide		Ala (A)	Arg (R)	Asx (N,D)	Cys (C)	Glx (Q,E)	Gly (G)	His (H)	Ile (I)	Leu (L)	Lys (K)	Met (M)	Phe (F)	Pro (P)	Ser (S)	Thr (T)	Trp (W)	Tyr (Y)	Val (V)
169 of 185	Expected			3	1		2		1	1	1	1	1			2			2
	Actual			3.0	0.9		2.0		1.1	1.0	1.0	0.9	1.0			2.0			2.0
170 of 185	Expected		1	2		1	1		2	1	1	1	1			2			2
	Actual		1.5	2.2		1.0	1.0		1.8	1.2	1.0	0.8	1.0			2.0			2.0
171 of 185	Expected	1	1	2		1	1		2	2		1	1		1	1			1
	Actual	1.0	0.9	1.9		1.0	1.0		1.8	1.8		0.8	0.9		1.0	1.1			1.0
172 of 185	Expected	2	1	1		1			2	2			1	1	1	1			1
	Actual	2.1	1.1	1.0		1.0			1.8	2.0			0.8	1.0	1.0	1.0			1.0
173 of 185	Expected	2		2		1		1	1	2	1			2	1	1			1
	Actual	2.1		1.8		1.0		1.2	1.1	1.9	1.1			2.3	0.9	1.0			0.7
174 of 185	Expected	2		2		2		1		1	1			2		1			2
	Actual	2.0		2.0		2.0		1.0		1.0	0.9			2.0		1.0			1.8
175 of 185	Expected	1		2		2		2		2	1		1	1					2
	Actual	1.0		2.0		2.0		2.0		2.0	1.2		1.3	1.0					1.8
176 of 185	Expected	1	1	1		2		1	1	2	1		1						3
	Actual	1.0	1.1	1.1		2.1		1.0	1.2	2.1	1.1		1.0						2.8
177 of 185	Expected		1	1		2		2	1	4	1		1						2
	Actual		1.3	1.1		2.1		2.0	1.1	4.1	1.1		1.0						1.8
178 of 185	Expected		1	1		1	1	2	1	3	1	1				1			1
	Actual		0.9	1.0		1.1	1.1	2.0	1.0	3.0	1.0	1.0				1.0			0.6
179 of 185	Expected			2		1	1	2		3		2			1	1			1
	Actual			2.0		1.0	1.0	2.0		3.0		1.9			1.2	1.0			0.9
180 of 185	Expected			3			1	1		2		3			1	2			1
	Actual			3.0			1.0	0.9		2.0		2.8			1.0	2.0			1.0
181 of 185	Expected		1	4						1		2			2	2			2
	Actual		1.6	4.1						1.0		2.0			1.9	2.0			1.6
182 of 185	Expected		1	3		2				1		1	1	1	1	2	1	1	
	Actual		1.0	2.7		2.0				1.0		1.0	1.0	1.1	0.9	2.0	b	1.0	
183 of 185	Expected	1	1	1		3						1	1	1	1	1	1	3	
	Actual	1.0	1.0	0.8		3.0						1.0	1.2	1.0	1.1	1.0	b	2.8	
184 of 185	Expected	1				3		1				1	1	2		2	1	2	1
	Actual	1.1				2.9		1.0				1.0	1.1	2.1		2.0	b	1.8	1.0
185 of 185	Expected	1				2		1		1		1		1		2		2	1
	Actual	1.0				2.1		1.0		1.1		1.0		1.2		2.0		1.8	1.0

⁴The following amino acids are sometimes excluded from the determination of peptide content since they often yield low values: Cysteine (C), tyrosine (Y) and tryptophan (W). Low values of Tryptophan are reported as b in the table.

Table 2: Peptide Solubility

Peptide	Sequence	Solubility	Solvent
1 of 185	1-SADAQSFLNRVCGVS-15	1 mg/mL	Water
2 of 185	6-SFLNRVCGVSAARLT-20	1 mg/mL	Water
3 of 185	11-VCGVSAARLTPCGTG-25	1 mg/mL	Water
4 of 185	16-AARLTPCGTGTSTDV-30	1 mg/mL	Water
5 of 185	21-PCGTGTSTDVVYRAF-35	1 mg/mL	Water
6 of 185	26-TSTDVVYRAFDIYND-40	1 mg/mL	Water
7 of 185	31-VYRAFDIYNDKVAGF-45	1 mg/mL	Water

Table 2: Peptide Solubility (continued)

Peptide	Sequence	Solubility	Solvent
8 of 185	36-DIYNDKVAGFAKFLK-50	1 mg/mL	Water
9 of 185	41-KVAGFAKFLKTNCCR-55	1 mg/mL	Water
10 of 185	46-AKFLKTNCCRFQEKD-60	1 mg/mL	Water
11 of 185 ⁵	51-TNCCRFQEKDEDDNL-65	1 mg/mL	Water
12 of 185 ⁵	56-FQEKDEDDNLIDSYF-70	1 mg/mL	Water
13 of 185	61-EDDNLIDSYFVVKRH-75	1 mg/mL	Water
14 of 185	66-IDSYFVVKRHTFSNY-80	1 mg/mL	Water
15 of 185	71-VVKRHTFSNYQHEET-85	1 mg/mL	Water
16 of 185	76-TFSNYQHEETIYNLL-90	1 mg/mL	Water
17 of 185	81-QHEETIYNLLKDCPA-95	1 mg/mL	Water
18 of 185	86-IYNLLKDCPAVAKH-100	1 mg/mL	Water
19 of 185	91-KDCPAVAKHDFKFR-105	1 mg/mL	Water
20 of 185	96-VAKHDFKFRIDGDM-110	1 mg/mL	Water
21 of 185	101-FFKFRIDGDMVPHIS-115	1 mg/mL	Water
22 of 185	106-IDGDMVPHISRQRLT-120	1 mg/mL	Water
23 of 185	111-VPHISRQRLTKYTMA-125	1 mg/mL	Water
24 of 185	116-RQRLTKYTMADLVYA-130	1 mg/mL	Water
25 of 185	121-KYTMADLVYALRHFD-135	1 mg/mL	Water
26 of 185 ⁵	126-DLVYALRHFDENCD-140	1 mg/mL	Water
27 of 185	131-LRHFDEGNCDTLKEI-145	1 mg/mL	Water
28 of 185	136-EGNCDTLKEILVTYN-150	1 mg/mL	Water
29 of 185 ⁵	141-TLKEILVTYNCCDDD-155	1 mg/mL	Water
30 of 185	146-LVTYNCCDDDFNKK-160	1 mg/mL	Water
31 of 185 ⁵	151-CCDDDFNKKDWYDF-165	1 mg/mL	Water
32 of 185	156-YFNKKDWYDFVENPD-170	1 mg/mL	Water
33 of 185	161-DWYDFVENPDILRVY-175	1 mg/mL	DMSO
34 of 185	166-VENPDILRVYANLGE-180	1 mg/mL	Water
35 of 185	171-ILRVYANLGERVRQA-185	1 mg/mL	Water
36 of 185	176-ANLGERVRQALLKTV-190	1 mg/mL	Water
37 of 185	181-RVRQALLKTVQFCDA-195	1 mg/mL	Water
38 of 185	186-LLKTVQFCDAMRNAG-200	1 mg/mL	Water
39 of 185	192-FCDAMRNAGIVGVL-205	1 mg/mL	Water
40 of 185	196-MRNAGIVGVLTLDNQ-210	1 mg/mL	Water
41 of 185	201-IVGVLTLDNQDLNGN-215	1 mg/mL	Water
42 of 185 ⁵	206-TLDNQDLNGNWDYDFG-220	1 mg/mL	Water
43 of 185 ⁵	211-DLNGNWDYDFGDFIQT-225	1 mg/mL	Water
44 of 185	216-WYDFGDFIQTTPGSG-230	1 mg/mL	Water
45 of 185	221-DFIQTTPGSGVPVVD-235	1 mg/mL	Water
46 of 185	226-TPGSGVPVVDSSYSL-240	1 mg/mL	Water
47 of 185	231-VPVVDSSYSLMPIL-245	1 mg/mL	DMSO

Table 2: Peptide Solubility (continued)

Peptide	Sequence	Solubility	Solvent
48 of 185	236-SYYSLLMPILTLTRA-250	1 mg/mL	DMSO
49 of 185	241-LMPILTLTRALTAES-255	1 mg/mL	Water
50 of 185	246-TLTRALTAESHVDTD-260	1 mg/mL	Water
51 of 185	251-LTAESHVDTDLTKPY-265	1 mg/mL	Water
52 of 185	256-HVDTDLTKPYIKWDL-270	1 mg/mL	Water
53 of 185	261-LTKPYIKWDLKYDF-275	1 mg/mL	Water
54 of 185	266-IKWDLKYDFTEERL-280	1 mg/mL	Water
55 of 185	271-LKYDFTEERLKLFD-285	1 mg/mL	Water
56 of 185	276-TEERLKLFD-290	1 mg/mL	Water
57 of 185	281-KLFD-295	1 mg/mL	Water
58 of 185	286-YFKYWDQTYHPNCVN-300	1 mg/mL	Water
59 of 185	291-DQTYHPNCVNCLDDR-305	1 mg/mL	Water
60 of 185	296-PNCVNCLDDRCILHC-310	1 mg/mL	Water
61 of 185	301-CLDDRCILHCANFNV-315	1 mg/mL	Water
62 of 185	306-CILHCANFNVLFSTV-320	1 mg/mL	Water
63 of 185	311-ANFNVLFSTVFPPTS-325	1 mg/mL	Water
64 of 185	316-LFSTVFPPTSFGPLV-330	1 mg/mL	DMSO
65 of 185	321-FPPTSFGPLVRKIFV-335	1 mg/mL	Water
66 of 185	326-FGPLVRKIFVDGVPF-340	1 mg/mL	Water
67 of 185	331-RKIFVDGVPFVSTG-345	1 mg/mL	Water
68 of 185	336-DGVPFVSTGYHFRE-350	1 mg/mL	Water
69 of 185	341-VVSTGYHFRELGVVH-355	1 mg/mL	Water
70 of 185	346-YHFRELGVVHNQDVN-360	1 mg/mL	Water
71 of 185	351-LGVVHNQDVNLHSSR-365	1 mg/mL	Water
72 of 185	356-NQDVNLHSSRSLFKE-370	1 mg/mL	Water
73 of 185	361-LHSSRSLFKELLVYA-375	1 mg/mL	Water
74 of 185	366-LSFKELLVYAADPAM-380	1 mg/mL	Water
75 of 185	371-LLVYAADPAMHAASG-385	1 mg/mL	Water
76 of 185	376-ADPAMHAASGNLLLD-390	1 mg/mL	Water
77 of 185	381-HAASGNLLLDKRTTC-395	1 mg/mL	Water
78 of 185	386-NLLLDKRTTCFSVAA-400	1 mg/mL	Water
79 of 185	391-KRTTCFSVAALTNNV-405	1 mg/mL	Water
80 of 185	396-FSVAALTNNVAFQTV-410	1 mg/mL	Water
81 of 185	401-LTNNVAFQTVKPGNF-415	1 mg/mL	Water
82 of 185	406-AFQTVKPGNFNKDFY-420	1 mg/mL	Water
83 of 185	411-KPGNFNKDFYDFAVS-425	1 mg/mL	Water
84 of 185	416-NKDFYDFAVSKGFFK-430	1 mg/mL	Water
85 of 185	421-DFAVSKGFFKEGSSV-435	1 mg/mL	Water
86 of 185	426-KGFFKEGSSVELKHF-440	1 mg/mL	Water
87 of 185	431-EGSSVELKHFFFAQD-445	1 mg/mL	Water

Table 2: Peptide Solubility (continued)

Peptide	Sequence	Solubility	Solvent
88 of 185	436-ELKHFFFAQDGNAAI-450	1 mg/mL	Water
89 of 185 ⁵	441-FFAQDGNAAISDYDY-455	1 mg/mL	Water
90 of 185	446-GNAAISDYDYRYNL-460	1 mg/mL	Water
91 of 185	451-SDYDYRYNLPTMCD-465	1 mg/mL	Water
92 of 185	456-YRYNLPTMCDIRQLL-470	1 mg/mL	Water
93 of 185	461-PTMCDIRQLLFVVEV-475	1 mg/mL	DMSO
94 of 185	466-IRQLLFVVEVVDKYF-480	1 mg/mL	DMSO
95 of 185 ⁵	471-FVVEVVDKYFDCYDG-485	1 mg/mL	Water
96 of 185	476-VDKYFDCYDGGCINA-490	1 mg/mL	Water
97 of 185	481-DCYDGGCINANQVIV-495	1 mg/mL	Water
98 of 185	486-GCINANQVIVNLDK-500	1 mg/mL	Water
99 of 185	491-NQVIVNLDKSAGFP-505	1 mg/mL	Water
100 of 185	496-NNLDKSAGFPFNKVG-510	1 mg/mL	Water
101 of 185	501-SAGFPFNKVGKARLY-515	1 mg/mL	Water
102 of 185	506-FNKVGKARLYYDSMS-520	1 mg/mL	Water
103 of 185	511-KARLYYDSMSYEDQD-525	1 mg/mL	Water
104 of 185 ⁵	516-YDSMSYEDQDALFAY-530	1 mg/mL	Water
105 of 185	521-YEDQDALFAYTKRNV-535	1 mg/mL	Water
106 of 185	526-ALFAYTKRNVIPTIT-540	1 mg/mL	Water
107 of 185	531-TKRNVIPTITQMNLK-545	1 mg/mL	Water
108 of 185	536-IPTITQMNLKYAISA-550	1 mg/mL	Water
109 of 185	542-MNLKYAISAKNRAR-555	1 mg/mL	Water
110 of 185	546-YAISAKNRARTVAGV-560	1 mg/mL	Water
111 of 185	551-KNRARTVAGVSICST-565	1 mg/mL	Water
112 of 185	556-TVAGVSICSTMTNRQ-570	1 mg/mL	Water
113 of 185	561-SICSTMTNRQFHQKL-575	1 mg/mL	Water
114 of 185	566-MTNRQFHQKLLKSIA-580	1 mg/mL	Water
115 of 185	571-FHQKLLKSIAATRGA-585	1 mg/mL	Water
116 of 185	576-LKSIAATRGA TVVIG-590	1 mg/mL	Water
117 of 185	581-ATRGATV VIGTSKFY-595	1 mg/mL	Water
118 of 185	586-TVVIGTSKFYGGWHN-600	1 mg/mL	Water
119 of 185	591-TSKFYGGWHNMLKTV-605	1 mg/mL	Water
120 of 185	596-GGWHNMLKTVYSDVE-610	1 mg/mL	Water
121 of 185	601-MLKTVYSDVENPHLM-615	1 mg/mL	Water
122 of 185 ⁵	606-YSDVENPHLMGWDYP-620	1 mg/mL	Water
123 of 185	611-NPHLMGWDYPKCDRA-625	1 mg/mL	Water
124 of 185	616-GWDYPKCDRAMPNML-630	1 mg/mL	Water
125 of 185	621-KCDRAMPNMLRIMAS-635	1 mg/mL	Water
126 of 185	626-MPNMLRIMASLVLAR-640	1 mg/mL	Water
127 of 185	631-RIMASLVLARKHTTC-645	1 mg/mL	Water

Table 2: Peptide Solubility (continued)

Peptide	Sequence	Solubility	Solvent
128 of 185	636-LVLARKHTTCCSLSH-650	1 mg/mL	Water
129 of 185	641-KHTTCCSLSHRFYRL-655	1 mg/mL	Water
130 of 185	646-CSLSHRFYRLANECA-660	1 mg/mL	Water
131 of 185	651-RFYRLANECAQVLSE-665	1 mg/mL	Water
132 of 185	656-ANECAQVLSEVMCG-670	1 mg/mL	Water
133 of 185 ³	662-VLSEVMCGGSLYV-675	1 mg/mL	Water
134 of 185	666-MVMCGGSLYVKPGGT-680	1 mg/mL	Water
135 of 185	671-GSLYVKPGGTSSGDA-685	1 mg/mL	Water
136 of 185	676-KPGGTSSGDATTAYA-690	1 mg/mL	Water
137 of 185	681-SSGDATTAYANSVFN-695	1 mg/mL	Water
138 of 185	686-TTAYANSVFNICQAV-700	1 mg/mL	Water
139 of 185	691-NSVFNICQAVTANVN-705	1 mg/mL	Water
140 of 185	696-ICQAVTANVNALLST-710	1 mg/mL	Water
141 of 185	701-TANVNALLSTDGNKI-715	1 mg/mL	Water
142 of 185	706-ALLSTDGNKIADKYV-720	1 mg/mL	Water
143 of 185	711-DGNKIADKYVRNLQH-725	1 mg/mL	Water
144 of 185	716-ADKYVRNLQHRLYEC-730	1 mg/mL	Water
145 of 185	721-RNLQHRLYECLYRNR-735	1 mg/mL	Water
146 of 185	726-RLYECLYRNRDVRTD-740	1 mg/mL	Water
147 of 185	731-LYRNRDVRTDFVNEF-745	1 mg/mL	Water
148 of 185	736-DVRTDFVNEFYAYLR-750	1 mg/mL	Water
149 of 185	741-FVNEFYAYLRKHFSM-755	1 mg/mL	Water
150 of 185	746-YAYLRKHFSMMILSD-760	1 mg/mL	Water
151 of 185	751-KHFSMMILSDDAVVC-765	1 mg/mL	Water
152 of 185	756-MILSDDAVVCFNSTY-770	1 mg/mL	Water
153 of 185	761-DAVVCFNSTYASQGL-775	1 mg/mL	Water
154 of 185	766-FNSTYASQGLVASIK-780	1 mg/mL	Water
155 of 185	771-ASQGLVASIKNFKSV-785	1 mg/mL	Water
156 of 185	776-VASIKNFKSVLYYQN-790	1 mg/mL	Water
157 of 185 ³	781-NFKSVLYYQNNVFMS-795	1 mg/mL	Water
158 of 185	786-LYYQNNVFMSEAKCW-800	1 mg/mL	Water
159 of 185	791-NVFMSEAKCWTETDL-805	1 mg/mL	Water
160 of 185	796-EAKCWTETDLTKGPH-810	1 mg/mL	Water
161 of 185	801-TETDLTKGPHEFCSQ-815	1 mg/mL	Water
162 of 185	806-TKGPHEFCSQHTMLV-820	1 mg/mL	Water
163 of 185	811-EFCSQHTMLVKQGDD-825	1 mg/mL	Water
164 of 185	816-HTMLVKQGDDYVYLP-830	1 mg/mL	Water
165 of 185	821-KQGDDYVYLPYDPS-835	1 mg/mL	Water
166 of 185	826-YVYLPYDPSRILGA-840	1 mg/mL	Water
167 of 185	831-YPDPSRILGAGCFVD-845	1 mg/mL	Water

Table 2: Peptide Solubility (continued)

Peptide	Sequence	Solubility	Solvent
168 of 185	836-RILGAGCFVDDIVKT-850	1 mg/mL	Water
169 of 185	841-GCFVDDIVKTDGTLTLM-855	1 mg/mL	Water
170 of 185	846-DIVKTDGTLMIERFV-860	1 mg/mL	Water
171 of 185	851-DGTLMIERFVSLAID-865	1 mg/mL	Water
172 of 185	856-IERFVSLAIDAYPLT-870	1 mg/mL	Water
173 of 185	861-SLAIDAYPLTKHPNQ-875	1 mg/mL	Water
174 of 185	866-AYPLTKHPNQEYADV-880	1 mg/mL	Water
175 of 185	871-KHPNQEYADVFLHYL-885	1 mg/mL	Water
176 of 185	876-EYADVFLHYLQYIRK-890	1 mg/mL	Water
177 of 185	881-FHLYLQYIRKLHDEL-895	1 mg/mL	Water
178 of 185	887-YIRKLHDELGHML-900	1 mg/mL	Water
179 of 185 ⁵	891-LHDELGHMLDMYSV-905	1 mg/mL	Water
180 of 185	896-TGHMLDMYSVMLTND-910	1 mg/mL	Water
181 of 185	901-DMYSVMLTNDNTSRY-915	1 mg/mL	Water
182 of 185	906-MLTNDNTSRYWEPEF-920	1 mg/mL	Water
183 of 185	911-NTSRYWEPEFYEAMY-925	1 mg/mL	Water
184 of 185 ⁵	916-WEPEFYEAMYPHTV-930	1 mg/mL	Water
185 of 185	921-YEAMYPHTVLQ-932	1 mg/mL	Water

⁵Ideally, reconstituted peptide solutions should be buffered to pH 5-6. But these peptides should be stored at pH > 8, after reconstitution.

/Sonia Bjorum Brower/

Sonia Bjorum Brower

22 FEB 2024

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by the vendor to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

